Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Keiley Elizabeth M
 2. Date of Event Requiring Statement (Month/Day/Year)
01/01/2015		 3. Issuer Name and Ticker or Trading Symbol
Oxford Immunotec Global PLC [OXFD]
(Last)
(First)
(Middle)
C/O OXFORD IMMUNOTEC GLOBAL, 94C INNOVATION DRIVE		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
VP & General Counsel
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

ABINGDON, OXFORDSHIRE, X0 OX14 4RZ		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Share Option (Right to Buy) (1)   (2) 09/30/2022 Ordinary Shares 11,185 $ 0.81 D  
Share Option (Right to Buy) (3)   (4) 01/01/2024 Ordinary Shares 6,030 $ 22.99 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Keiley Elizabeth M
C/O OXFORD IMMUNOTEC GLOBAL
94C INNOVATION DRIVE
ABINGDON, OXFORDSHIRE, X0 OX14 4RZ		       VP & General Counsel  

Signatures

/s/ Elizabeth M. Keiley 01/06/2014
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Option granted under Issuer's Amended and Restated 2008 Stock Incentive Plan.
(2) Currently exercisable as to 6,291 shares, and will become exercisable as to the remainder ratably on the first of each month from February 1, 2015 through October 1, 2016.
(3) Option granted under Issuer's 2013 Share Incentive Plan.
(4) Currently exercisable as to 1,507 shares, and will become exercisable as to the remainder ratably on the first of each month from February 1, 2015 through January 1, 2018.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.